Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis (MSSkin)

This study has been completed.
Teva Pharmaceutical Industries
Information provided by (Responsible Party):
University of North Carolina, Charlotte Identifier:
First received: September 2, 2009
Last updated: March 6, 2012
Last verified: March 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2010
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)